TW202432120A - 注射用組合物、包含其之醫藥調配物以及製備該組合物之方法 - Google Patents
注射用組合物、包含其之醫藥調配物以及製備該組合物之方法 Download PDFInfo
- Publication number
- TW202432120A TW202432120A TW112144715A TW112144715A TW202432120A TW 202432120 A TW202432120 A TW 202432120A TW 112144715 A TW112144715 A TW 112144715A TW 112144715 A TW112144715 A TW 112144715A TW 202432120 A TW202432120 A TW 202432120A
- Authority
- TW
- Taiwan
- Prior art keywords
- injection
- composition
- albumin
- sbe
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2023-0013947 | 2023-02-01 | ||
| KR20230013947 | 2023-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202432120A true TW202432120A (zh) | 2024-08-16 |
Family
ID=92024104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112144715A TW202432120A (zh) | 2023-02-01 | 2023-11-20 | 注射用組合物、包含其之醫藥調配物以及製備該組合物之方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4658244A1 (https=) |
| JP (1) | JP2026505092A (https=) |
| KR (1) | KR20240121186A (https=) |
| CN (1) | CN118415999A (https=) |
| AR (1) | AR131668A1 (https=) |
| AU (1) | AU2024215883A1 (https=) |
| CL (1) | CL2025002270A1 (https=) |
| CO (1) | CO2025011347A2 (https=) |
| DO (1) | DOP2025000185A (https=) |
| IL (1) | IL322431A (https=) |
| JO (1) | JOP20250189A1 (https=) |
| MX (1) | MX2025008735A (https=) |
| PE (1) | PE20252396A1 (https=) |
| TW (1) | TW202432120A (https=) |
| WO (1) | WO2024161316A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120827558A (zh) * | 2024-04-19 | 2025-10-24 | 丽珠医药集团股份有限公司 | 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682133A1 (en) * | 2003-11-03 | 2006-07-26 | AstraZeneca AB | Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| AR051041A1 (es) * | 2004-10-04 | 2006-12-13 | Altana Pharma Ag | Bencimidazoles triciclicos condensados |
| FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| KR101777971B1 (ko) * | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
-
2023
- 2023-11-20 TW TW112144715A patent/TW202432120A/zh unknown
- 2023-11-29 CN CN202311609051.XA patent/CN118415999A/zh active Pending
-
2024
- 2024-01-23 AR ARP240100149A patent/AR131668A1/es unknown
- 2024-01-31 PE PE2025001666A patent/PE20252396A1/es unknown
- 2024-01-31 AU AU2024215883A patent/AU2024215883A1/en active Pending
- 2024-01-31 KR KR1020240014951A patent/KR20240121186A/ko active Pending
- 2024-01-31 IL IL322431A patent/IL322431A/en unknown
- 2024-01-31 EP EP24749813.2A patent/EP4658244A1/en active Pending
- 2024-01-31 WO PCT/IB2024/050869 patent/WO2024161316A1/en not_active Ceased
- 2024-01-31 JP JP2025544851A patent/JP2026505092A/ja active Pending
-
2025
- 2025-07-25 MX MX2025008735A patent/MX2025008735A/es unknown
- 2025-07-28 JO JOJO/P/2025/0189A patent/JOP20250189A1/ar unknown
- 2025-07-30 CL CL2025002270A patent/CL2025002270A1/es unknown
- 2025-07-31 DO DO2025000185A patent/DOP2025000185A/es unknown
- 2025-08-22 CO CONC2025/0011347A patent/CO2025011347A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR131668A1 (es) | 2025-04-16 |
| CO2025011347A2 (es) | 2025-09-18 |
| IL322431A (en) | 2025-09-01 |
| KR20240121186A (ko) | 2024-08-08 |
| AU2024215883A1 (en) | 2025-07-31 |
| JP2026505092A (ja) | 2026-02-10 |
| CN118415999A (zh) | 2024-08-02 |
| MX2025008735A (es) | 2025-11-03 |
| DOP2025000185A (es) | 2026-02-15 |
| EP4658244A1 (en) | 2025-12-10 |
| CL2025002270A1 (es) | 2025-10-03 |
| JOP20250189A1 (ar) | 2025-07-28 |
| PE20252396A1 (es) | 2025-10-10 |
| WO2024161316A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5936546B2 (ja) | ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミドのメグルミン塩 | |
| ES2626236T3 (es) | Uso de polioles para obtener formas polimorfas estables de rifaximina | |
| RU2770366C2 (ru) | Препараты даптомицина | |
| EP0649655A1 (en) | Injectable solutions containing anti-ulcer benzimidazoles and amides | |
| JP6461945B2 (ja) | ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法 | |
| CN110876259B (zh) | 注射用组合物 | |
| JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| JPWO2006134877A1 (ja) | 注射剤 | |
| JP2006500367A (ja) | ブチルフタリドとシクロデキストリンまたはその誘導体との包接複合体、それらの調製のためのプロセスおよびその使用 | |
| TW202432120A (zh) | 注射用組合物、包含其之醫藥調配物以及製備該組合物之方法 | |
| KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
| CN102516298A (zh) | 左旋奥硝唑磷酸酯稳定的药用盐及其制备方法和用途 | |
| JP6063064B2 (ja) | 安定したノカチアシン凍結乾燥製剤 | |
| KR20070026187A (ko) | 2개 이상의 활성 물질을 함유하는 주사용 멸균 약제학적제형 | |
| JPH0136445B2 (https=) | ||
| HK40111340A (zh) | 可注射组合物、包含其的药物制剂以及制备该组合物的方法 | |
| EA008145B1 (ru) | Инъецируемая галеновая форма флупиртина | |
| CN102516299A (zh) | 左旋奥硝唑磷酸酯氨基酸盐及其制备方法和用途 | |
| JPH1180021A (ja) | バンコマイシン注射剤 | |
| KR100973470B1 (ko) | 칼시토닌-폴리포스페이트의 복합체 및 그의 제조방법 | |
| KR20080099562A (ko) | 안정한 고체분산체 함유 약학조성물 | |
| CN1589795A (zh) | 尼莫地平冻干组合物及其制备方法 | |
| JP2002080361A (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 | |
| RU2285696C2 (ru) | Комплексы включения бутилфталида с циклодекстрином или его производными, способ их получения и их применение | |
| US10294275B2 (en) | Site-selective functionalization of glycopeptide antibiotics |